Results of a randomized, open-label, clinical trial investigating the effects of supplementation with Heracleum persicum extract as an adjunctive therapy for dyslipidemia

Panahi, Y. and Pishgoo, B. and Beiraghdar, F. and Araghi, Z. M. and Sahebkar, A. and Abolhasani, E. (2011) Results of a randomized, open-label, clinical trial investigating the effects of supplementation with Heracleum persicum extract as an adjunctive therapy for dyslipidemia. TheScientificWorldJournal, 11. pp. 592-601.

[img] Text
Results of a randomized, open-label, clinical trial investigating the effects of supplementation with Heracleum persicum extract as an adjunctive therapy for dyslipidemia.pdf

Download (686kB)
[img] Text
TSWJ-2011-11-868459.pdf

Download (686kB)

Abstract

The present study evaluated the potential benefit of supplementation with Heracleum persicum as an adjunctive therapy to atorvastatin in dyslipidemic subjects. In a randomized, open-label, clinical trial, 100 dyslipidemic subjects were randomly assigned to: (1) H. persicum group (n = 50, completers = 18), receiving H. persicum extract (500 mg/day) + atorvastatin (10 mg/day) for 8 weeks, or (2) atorvastatin group (n = 50, completers = 34), receiving only atorvastatin (20 mg/day) for 8 weeks. Weight, body mass index (BMI), lipid profile, and biomarkers of hepatic and renal injury were determined at baseline and at the end of the trial. There were significant reductions in serum total cholesterol and LDL-C in both the H. persicum (p = 0.001) and atorvastatin (p < 0.001) groups. Serum HDL-C was elevated in the atorvastatin group (p < 0.05), while no significant change was observed in the H. persicum group (p > 0.05). Serum triglyceride levels remained statistically unchanged by the end of the trial in both groups (p > 0.05). Serum alanine (p = 0.049) and aspartate aminotransferase (p = 0.013) levels rose in the atorvastatin, but not the H. persicum (p > 0.05) group. In comparison with baseline values, no significant change was observed in weight and BMI, as well as serum levels of creatinine, blood urea nitrogen, and fasting blood sugar in either of the groups (p > 0.05). Apart from HDL-C, the effects of atorvastatin (20 mg/day) on other lipid profile parameters do not appear to be significantly superior to those achieved by combination therapy with H. persicum + atorvastatin (10 mg/day). ©2011 with author. Published by TheScientificWorld.

Item Type: Article
Additional Information: Cited By :19 Export Date: 16 February 2020 Correspondence Address: Panahi, Y.; Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran; email: yunespanahi@yahoo.com
Uncontrolled Keywords: Atorvastatin Cholesterol Dyslipidemia Heracleum persicum Triglycerides alanine aminotransferase aspartate aminotransferase creatinine Heracleum persicum extract high density lipoprotein cholesterol hypocholesterolemic agent lipicom low density lipoprotein cholesterol plant extract triacylglycerol unclassified drug adult aged article body mass body weight cholesterol blood level creatinine blood level diet supplementation female glucose blood level human kidney injury liver injury major clinical study male medicinal plant randomized controlled trial triacylglycerol blood level urea nitrogen blood level Aged, 80 and over Body Mass Index Dietary Supplements Dyslipidemias Heptanoic Acids Heracleum Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Middle Aged Plant Extracts Pyrroles
Subjects: QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib7 lib7
Date Deposited: 03 May 2020 04:12
Last Modified: 03 May 2020 04:12
URI: http://eprints.mums.ac.ir/id/eprint/17090

Actions (login required)

View Item View Item